Welcome LEO Pharma
Founded in 1908, LEO Pharma is a foundation-owned company that has devoted decades of research and development to...
ARCHIVE
DOACs in the treatment of cancer-associated thrombosis
Since the publication of the SELECT-D trial1 and the Hokusai-VTE Cancer study2, there has been a shift in the...
An update on the status of direct oral anticoagulants in children
Introduction Once considered a condition of adults or the elderly, venous thromboembolism (VTE) is now being recognized...
Venous thromboembolism in blood or marrow transplant recipients
Cancer is a well-recognized risk factor for venous thromboembolism (VTE) and several risk prediction models have been...
VIII Forum of Thrombosis Oncology
The VIII Oncology Forum on Thrombosis is going to be held in Madrid, 22-23 February 2019. The course has already...
The safety of DOACs to treat VTE in patients with brain tumors
Patients with primary and metastatic brain tumors have a high risk of venous thromboembolism (VTE), occurring in 20-30%...
Developmental hemostasis and its relevance to pediatric thrombosis
The coagulation system of neonates and children evolves with age, as evidenced by marked physiological differences in...
Arterial thrombosis and pediatric cancer- should cancer associated pediatric stroke be studied?
While knowledge of arterial thromboembolism prevalence and risk factors among adult cancer patients is currently...
Should we test pediatric cancer patients for thrombophilia: NO
Cancer is the second most common cause of death in children in developed countries. Fortunately, survival rates have...
Should we test pediatric cancer patients for thrombophilia: YES
Venous thromboembolism (VTE) in children is a rare disease usually as a secondary complication of primary underlying...